Nasdaq · Healthcare
Axogen, Inc. (AXGN)
As-reported financials and recent SEC filings for Axogen, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$225.2M
Net income
$-15.7M
Net margin
-7.0%
Diluted EPS
$-0.34
ROE
-12.2%
P/E (TTM)
—
Market cap
—
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $225.2M | $187.3M | $159.0M | $138.6M | $127.4M |
| Gross profit | $167.4M | $142.0M | $121.9M | $108.8M | $104.4M |
| Operating income | $-7.8M | $-3.3M | $-21.5M | $-29.7M | $-25.4M |
| Net income | $-15.7M | $-10.0M | $-21.7M | $-28.9M | $-27.0M |
| Diluted EPS | $-0.34 | $-0.23 | $-0.51 | $-0.69 | $-0.65 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-23
View on EDGAR →Largest Healthcare peers
Go deeper on AXGN
Search Axogen, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.